TY - JOUR
T1 - Emerging Application of Nanorobotics and Artificial Intelligence to Cross the BBB
T2 - Advances in Design, Controlled Maneuvering, and Targeting of the Barriers
AU - Singh, Ajay Vikram
AU - Chandrasekar, Vaisali
AU - Janapareddy, Poonam
AU - Mathews, Divya Elsa
AU - Laux, Peter
AU - Luch, Andreas
AU - Yang, Yin
AU - Garcia-Canibano, Beatriz
AU - Balakrishnan, Shidin
AU - Abinahed, Julien
AU - Al Ansari, Abdulla
AU - Dakua, Sarada Prasad
N1 - Publisher Copyright:
© 2021 American Chemical Society.
PY - 2021/6/2
Y1 - 2021/6/2
N2 - The blood-brain barrier (BBB) is a prime focus for clinicians to maintain the homeostatic function in health and deliver the theranostics in brain cancer and number of neurological diseases. The structural hierarchy and in situ biochemical signaling of BBB neurovascular unit have been primary targets to recapitulate into the in vitro modules. The microengineered perfusion systems and development in 3D cellular and organoid culture have given a major thrust to BBB research for neuropharmacology. In this review, we focus on revisiting the nanoparticles based bimolecular engineering to enable them to maneuver, control, target, and deliver the theranostic payloads across cellular BBB as nanorobots or nanobots. Subsequently we provide a brief outline of specific case studies addressing the payload delivery in brain tumor and neurological disorders (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.). In addition, we also address the opportunities and challenges across the nanorobots' development and design. Finally, we address how computationally powered machine learning (ML) tools and artificial intelligence (AI) can be partnered with robotics to predict and design the next generation nanorobots to interact and deliver across the BBB without causing damage, toxicity, or malfunctions. The content of this review could be references to multidisciplinary science to clinicians, roboticists, chemists, and bioengineers involved in cutting-edge pharmaceutical design and BBB research.
AB - The blood-brain barrier (BBB) is a prime focus for clinicians to maintain the homeostatic function in health and deliver the theranostics in brain cancer and number of neurological diseases. The structural hierarchy and in situ biochemical signaling of BBB neurovascular unit have been primary targets to recapitulate into the in vitro modules. The microengineered perfusion systems and development in 3D cellular and organoid culture have given a major thrust to BBB research for neuropharmacology. In this review, we focus on revisiting the nanoparticles based bimolecular engineering to enable them to maneuver, control, target, and deliver the theranostic payloads across cellular BBB as nanorobots or nanobots. Subsequently we provide a brief outline of specific case studies addressing the payload delivery in brain tumor and neurological disorders (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.). In addition, we also address the opportunities and challenges across the nanorobots' development and design. Finally, we address how computationally powered machine learning (ML) tools and artificial intelligence (AI) can be partnered with robotics to predict and design the next generation nanorobots to interact and deliver across the BBB without causing damage, toxicity, or malfunctions. The content of this review could be references to multidisciplinary science to clinicians, roboticists, chemists, and bioengineers involved in cutting-edge pharmaceutical design and BBB research.
KW - Blood-brain barrier
KW - bioengineering
KW - machine learning and artificial intelligence
KW - nanoparticles
KW - nanorobots
KW - transcytosis
UR - https://www.scopus.com/pages/publications/85107711540
U2 - 10.1021/acschemneuro.1c00087
DO - 10.1021/acschemneuro.1c00087
M3 - Review article
C2 - 34008957
AN - SCOPUS:85107711540
SN - 1948-7193
VL - 12
SP - 1835
EP - 1853
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 11
ER -